Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor

Mai, Shijie; Xiong, Gang; Diao, Dingwei; Wang, Wenjing; Zhou, Yujie; Cai, Rong

doi:10.1016/j.lungcan.2018.12.016

Cited by 30 publications

(32 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 Crizotinib has also shown remarkable efficacy against ROS1-positive lung cancer and was the first TKI approved for ROS1-positive advanced NSCLC. 21 A patient aged 14 years with pulmonary IMT with a TFG-ROS1 fusion achieved continuous remission 22 and a boy aged 8 years with treatment-refractory ALK-negative IMT harboring a TFG-ROS1 fusion experienced a dramatic response after treatment with crizotinib. 8 However, another study found that a patient aged 59 years with metastatic gastric IMT carrying a TFG-ROS1 fusion and treated with crizotinib showed a poor response.…”

Section: Discussionmentioning

confidence: 99%

Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion

Li¹,

Chen²,

Qu³

et al. 2019

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

Inflammatory myofibroblastic tumor (IMT), a rare sarcoma, is primarily treated via resection of the mass. However, there is no standard treatment for recurrence or unresectable tumors. Almost 50% of IMTs carry ALK gene rearrangement that can be treated using ALK inhibitors, but therapeutic options for ALK-negative tumors are limited. This report describes a woman aged 22 years with unresectable ALK-negative IMT. Next-generation sequencing revealed a TFG-ROS1 fusion, and she had a partial response to the ROS1 inhibitor ceritinib. This report provides the first published demonstration of a patient with IMT with ROS1 fusion successfully treated using ceritinib. Our study suggests that targeting ROS1 fusions using the small molecule inhibitor shows promise as an effective therapy in patients with IMT carrying this genetic alteration, but this requires further investigation in large clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion

Li¹,

Chen²,

Qu³

et al. 2019

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

show abstract

“…[ 7 ] Moreover, symptoms subsided after chemotherapy with drugs such as crizotinib and clarithromycin. [ 8 , 9 ] In this article, we report the case of an ALK-negative IMT that showed symptoms of an ulnaris nerve lesion, with the tumor occurring and growing rapidly in the triceps brachii muscle, within the limb musculoskeletal system, before improvement of the symptoms with surgical treatment. [ 10 ]…”

Section: Introductionmentioning

confidence: 99%

Anaplastic lymphoma receptor tyrosine kinase-negative inflammatory myofibroblastic tumor of triceps brachii: Case report

Lee¹

2020

Jt Dis Relat Surg

View full text Add to dashboard Cite

“…They all bene ted from treatment with crizotinib (250 mg) with a signi cant reduction in tumor size. (31)(32)(33)(34) Jia He et al found for the rst time a double ampli cation of CDK4 and MDM2 with protein overexpression by NGS and IHC in a 68-year-old woman with a gastric IMT with local invasion of spleen and diaphragm (35). Furthermore, Antonescu et al found correlations between the genotypes and certain clinic-pathologic characteristics of the IMT .…”

Section: Discussionmentioning

confidence: 99%

ALK-Negative Lung Inflammatory Myofibroblastic Tumor in a Young Adult: a Case Report and Literature Review of Molecular Alterations

Debonis

Bongiovanni

Pieri

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor and is prevalent among children and adolescents. Surgery is the most important therapeutic approach for IMT and complete resection is recommended. Although 50% of IMTs present anaplastic lymphoma kinase (ALK) rearrangements, an efficacy has been shown by the use of Crizotinib . However the genetic landscape of this tumor is not fully understood and the therapeutic options are limited in particular for the remaining percentage of negative ALK tumors. Case presentation: In our case, we detail the clinical history of 18-year-old female patient diagnosed with pulmonary IMT negative for ALK, subjected to surgery and subsequently to follow-up. The initial pathology report oriented for a salivary gland lung cancer. Afterwards due to a second look by another pathologist an ALK negative IMT of the lung was diagnosed. We also perform a literature review based on IMT and other kinase fusions found in addition to ALK such as ROS proto-oncogene 1 (ROS1), rearranged during transfection (RET), neurotrophic receptor tyrosine kinases (NTRKs) and platelet derived growth factor receptor (PDGFR beta). Conclusions: IMT is a very rare disease involving children and adolescents. Little is known about the clinical and molecular characteristics, pathological diagnosis, prognosis and optimal management strategy of IMT. Since there is no "standard of care" therapy for IMT, identifying feasible genomic alterations could redefine the management of patients with negative ALK disease.

show abstract

Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor

Cited by 30 publications

References 8 publications

Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion

Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion

Anaplastic lymphoma receptor tyrosine kinase-negative inflammatory myofibroblastic tumor of triceps brachii: Case report

ALK-Negative Lung Inflammatory Myofibroblastic Tumor in a Young Adult: a Case Report and Literature Review of Molecular Alterations

Contact Info

Product

Resources

About